In this Section |
218995 Prevalence and predictors of HCV related risk behaviors in recent and prolonged injection drug users in Metropolitan San Juan, Puerto RicoTuesday, November 9, 2010
Considering that Puerto Ricans are undergoing a public health problem with respect to HCV infection, an endemic infection among injecting drug users (IDUs) in response to risk behaviors conducted, and that there is a high frequency of drug injection in settings where sterile injection equipment are low, it is essential to understand the burden of risk behaviors and its correlates. This study assessed the prevalence of risk behaviors within recent and prolonged IDUs (study groups) and examined correlates of risk behaviors in IDUs aged 18 years at least living in the San Juan Metropolitan Area. We analyzed data from the cross-sectional study, entitled 'The PR drug abuse research development program' that used a sample of 400 IDUs. IDUs were classified as recent (<3 years of injection) and prolonged (>3 years of injection). Overall prevalence of sharing water within study groups was 48% and 63.3%, respectively; prevalence of sharing a cooker within study groups was 50% and 66.7%, respectively; and prevalence of sharing syringes within study groups was 28.4% and 37%, respectively. Binary logistic regression showed that prolonged injectors were more likely to share water, the cooker and syringes compared to recent injectors after adjusting for gender and homelessness (OR:1.86; 95%CI:1.18-2.93, OR:2.03; 95%CI:1.28-3.22 and OR:1.53; 95%CI:0.93-2.51, respectively). Comprehensive efforts to prevent risky practices should address social and environmental contexts of injection, considering differences in IDUs according to their years of injection.
Learning Areas:
EpidemiologyImplementation of health education strategies, interventions and programs Other professions or practice related to public health Planning of health education strategies, interventions, and programs Program planning Social and behavioral sciences Learning Objectives: Keywords: Intravenous Drug Use, Hepatitis C
Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: N/A Qualified on the content I am responsible for because: I am qualified to present because I am a current student of Master of Science degree in Epidemiology at UPR-RCM., who is performing her Masters theses in Injection Drug Use and HCV. Furthermore, I had different extracurricular experiences, such as being involve in the data collection of an environmental study sponsored by EPA (Interviewer for the National Beaches Survey) and in performing a research as a Dr. James A. Ferguson Research Fellow 2008 (Development of a serotype-specific assay for the detection of dengue virus NS1 in human serum.). This research was sponsored by CDC and AMHPS. Currently, I am the research coordinator of a pilot study based on metabolic syndrome in adolescents (Relation of body mass index to future risk of type 2 diabetes, cardiovascular disease and cancer in Puerto Rican adolescents: An evaluation of the contribution by adipocytokines, insulin resistance and inflammation; PI: C.M.Perez, PhD; CoPI: A.P.Ortiz, PhD). This pilot study will be conducted at the RCM-CRC. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 4130.0: Drug Use Across the Globe
|